Cargando…
Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
Ferroptosis, a form of programed cell death, can be promoted by inhibitors of the xCT transporter (erastin) or GPX4 (RSL3). We found that GPX4, but not the xCT transporter, is selectively elevated in luminal breast cancer. Consistent with this observation, the majority of luminal breast cancer cell...
Autores principales: | Park, Soon Young, Jeong, Kang Jin, Poire, Alfonso, Zhang, Dong, Tsang, Yiu Huen, Blucher, Aurora S., Mills, Gordon B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439209/ https://www.ncbi.nlm.nih.gov/pubmed/37596261 http://dx.doi.org/10.1038/s41419-023-06042-1 |
Ejemplares similares
-
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013) -
HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013) -
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021) -
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
por: Luque-Cabal, María, et al.
Publicado: (2016) -
Luminal B breast tumors are not HER2 positive
por: Bhargava, Rohit, et al.
Publicado: (2008)